# Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

> **NCT04729387** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 358 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Alpelisib
- **DRUG:** Olaparib
- **DRUG:** Paclitaxel
- **DRUG:** Pegylated liposomal doxorubicin (PLD)

## Key facts

- **NCT ID:** NCT04729387
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-22
- **Primary completion:** 2023-04-21
- **Final completion:** 2026-01-19
- **Target enrollment:** 358 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04729387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04729387, "Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04729387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*